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Background: Insulin like growth factor binding protein 7 (IGFBP7) is a secreted protein binding insulin like growth
factor 1 (IGF-1), insulin, vascular endothelial growth factor A (VEGFA), and activin A. It antagonizes bone
morphogenetic proteins and is involved in the tumour propagation of solid as well as haematological malignancies.
Its role in multiple myeloma (MM) is not defined so far. We therefore aim here to investigate its prognostic and
pathophysiological role in MM.
Methods: The clinical significance of IGFBP7 gene expression was investigated by gene expression profiling in two
independent cohorts (n = 948) of newly-diagnosed MM patients. Methylation of the IGFBP7 promoter was analysed
by pyrosequencing and treatment of MM cell lines with 5-aza-2-deoxycytidine. The impact of IGFBP7 on MM cells
was studied by CCK-8 assay, BrdU assay and flow cytometry, respectively. IGFBP7 expression in bone marrow stromal
cells (BMSCs) was studied by quantitative RT-PCR. For osteoblast development, immortalized and primary human
BMSCs were cultured in osteogenic differentiation medium for 7–14 days in the presence of recombinant human
IGFBP7 and/or activin A.
Results: Median IGFBP7 expression is significantly lower in CD138-purified plasma cells from individuals with MGUS and
MM, compared to normal bone marrow plasma cells. IGFBP7 gene expression in MM cells is regulated by methylation,
shown by pyrosequencing and exposure to demethylating agents (5-aza-2-deoxycytidine). High expression of IGFBP7 in
MM cells is associated with adverse survival in two independent cohorts of 247 and 701 newly-diagnosed MM patients
treated with high-dose therapy and autologous stem cell transplantation. IGFBP7 is associated with prognostically
adverse chromosomal aberrations (t(4;14) and gain of 1q21), MMSET expression, and higher myeloma cell proliferation. In
vitro, IGFBP7 overcomes activin A induced osteoblast suppression and promotes osteogenesis. MM cells downregulate
IGFBP7 in stromal cells, possibly contributing to the osteoblast suppression found in MM. Conversely, higher IGFBP7
expression is associated with a lower probability of myeloma bone disease.
Conclusions: Our data indicate that IGFBP7 expression is a marker for a specific methylation pattern in myeloma, linked
to translocation t(4;14) associated MMSET expression, showing clinical features of adverse prognosis with absence of
myeloma bone disease.
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Multiple myeloma (MM) is characterized by the accumu-
lation of malignant plasma cells (PCs) in the bone marrow
(BM) [1]. MM cells reside in the BM microenvironment
similar to their normal counterparts where they receive
essential survival and growth signals from the surrounding
stromal compartments [2]. Direct interactions between
myeloma cells and bone marrow stromal cells (BMSCs) or
osteoclasts [3] as well as the crosstalk through various sol-
uble factors play a major role in the pathophysiology of
MM leading to clinical features such as myeloma bone
disease, anaemia and immunosuppression [1].
MM cells are closely connected with BMSCs, modify
their function and induce the production of tumour pro-
moting factors [4]. Within the growth signalling network
of the myeloma microenvironment, IL-6, IGF-1 and in-
sulin play a prominent role [5-7]. An imbalance of the
RANKL to OPG ratio promotes osteoclast activation [8]
while the secretion of osteoblast inhibitory molecules
such as DKK-1 and activin A impairs osteogenesis, lead-
ing to myeloma induced bone disease [9,10].
Bone morphogenetic proteins (BMPs) in turn stimu-
late bone formation [11] and are at the same time potent
inhibitors of MM cell survival [12,13]. Higher BMP ex-
pression in malignant plasma cells is associated with su-
perior overall survival [13]. Less is known, however,
about the role of BMP antagonists in MM. In solid ma-
lignancies, upregulation of BMP antagonists such as
gremlin was shown to promote the growth and survival
of tumour cells [14]. We therefore speculated that de-
regulation of BMP antagonistic proteins in the myeloma
microenvironment might be involved in the pathophysi-
ology of MM. To address this question, we analysed the
BMP antagonist expression profile in myeloma, identify-
ing insulin like growth factor binding protein 7 (IGFBP7)
as a potential gene of interest. IGFBP7 is a secreted pro-
tein with IGF-1, insulin [15], VEGFA [16] and activin A
[17] binding properties and has been described as BMP
antagonist [18]. Methylation dependent silencing of
IGFBP7 was reported as associated with unfavourable
outcome in lung-, breast-, and pancreatic cancer, as
well as hepatocellular carcinoma [19-23]. On the con-
trary, high IGFBP7 expression was linked to poor prog-
nosis in oesophageal adenocarcinoma as well as head
and neck squamous cell carcinomas [24,25]. Recent stud-
ies also suggested a role for IGFBP7 in haematological
malignancies. In acute lymphoblastic leukemia (ALL)
IGFBP7 expression was associated with adverse outcome
and shown to interfere with leukemia cell proliferation
[26,27]. IGFBP7 was also reported to be involved in the
crosstalk between BMSCs and ALL cells, mediating
asparaginase-resistance in B-lineage ALL cells [27]. Based
on these results we were interested in the prognostic and
pathophysiologic role of IGFBP7 in MM.Results
IGFBP7 gene expression is downregulated in myeloma cells
IGFBP7 gene expression levels were significantly de-
creased in a series (HM group) of CD138 sorted
plasma cells from MGUS (n = 22) and MM patient
samples (n = 332) as well as in human myeloma cell
lines (HMCLs) (n = 32) compared to normal plasma
cells (n = 10) (P < 0.02) whereas IGFBP7 expression
was absent in memory B cells (MBCs) and proliferating
polyclonal plasmablastic cells (PPCs) (Figure 1A). IGFBP7
gene expression was detectable in 100% of purified bone
marrow plasma cells from healthy individuals, compared
to 45.5% of samples from MGUS patients, 47.7% from
MM patients, 47.1% of HMCLs and 0% of MBCs and
PPCs, respectively. Expression levels varied widely in bone
marrow plasma cell samples from myeloma patients as
well as in HMCLs, the latter confirmed by PCR analysis
(Figure 1B) and flow cytometry (Figure 1C). Other fac-
tors related to BMP antagonism dysregulated in MM
are listed in Additional file 1: Table S1 and Additional
file 2: Table S2.
IGFBP7 gene expression is regulated via methylation
Exposure of HMCLs to the demethylating agent 5-aza-2′
deoxycytidine (aza) and/or the histone deacetylase inhibi-
tor Trichostatin A (TSA) showed significant upregulation
of IGFBP7 mRNA levels in 4 of 6 cell lines tested (median
upregulation with aza + TSA: 3.05; range: 1.83 – 21.47;
P < 0.05) (Figure 2A). In addition, in KMS-12-BM,
IGFBP7 expression changed from not detectable by qPCR
in the DMSO control to detectable with aza treatment
(not shown). To validate these results, we analysed the
promoter methylation status of IGFBP7 in a “low” (KMS-
12-BM) and “high” (OPM-2) expressing MM cell line as
well as in CD138 purified cells of four myeloma patients.
Pyrosequencing demonstrated methylation of the IGFBP7
promoter region generally in accordance with the IGFBP7
gene expression levels by qPCR (Figure 2B). The methyla-
tion status of one patient, however, was not in line with
the qPCR results, showing no methylation in the analysed
promoter region despite suppressed IGFBP7 expression.
This suggests that methylation of other regulatory regions
or other mechanisms might mediate downregulation of
IGFBP7 gene expression in certain MM cases.
IGFBP7 gene expression in MM cells of patients is linked
to adverse survival and poor risk cytogenetics
IGFBP7 gene expression in MM cells was significantly
associated with event free survival (EFS) and overall sur-
vival (OS) in both patient cohorts analysed. Patients with
high IGFBP7 expression levels had a significantly worse
outcome compared to those with low IGFBP7 expression
in the HM (median EFS: 34.2 vs. 22.6 months, P < 0.001;













































Figure 1 Insulin like growth factor binding protein 7 (IGFBP7) is downregulated in multiple myeloma. (A) IGFBP7 expression levels were
analysed by gene expression profiling of memory B cells (MBC), polyclonal plasmablastic cells (PPC) as well as of CD138+ purified cells from healthy
donors (BMPC), newly diagnosed myeloma patients (MM), patients suffering from monoclonal gammopathy of undetermined significance (MGUS) and
human MM cell lines (HMCLs). Grey data points indicate an absent, black data points a present Affymetrix detection call. The asterisk indicates
statistical significance (* P < 0.02). IGFBP7 expression analysis by qPCR (B) and flow cytometry (C) confirmed heterogeneous expression levels in
myeloma cell lines. (B) Expression levels by qPCR are displayed relative to peripheral blood mononuclear cells (PBMCs) of healthy donors (n = 3).
IGFBP7 expression in PBMCs was arbitrarily set at 1. (C) Intracellular staining of MM cells for IGFBP7 protein levels confirmed the variable expression of
IGFBP7 transcripts observed by qPCR. MM cells were stained with either anti-IGFBP7 antibody (black lines) or control antibody (light grey lines),
followed by PE-conjugated anti-goat antibody.
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methylation [%]  2.1       68.9      20.3      1.5        43.9      3.6
Figure 2 IGFBP7 is silenced via methylation. (A) MM cell lines were treated with DMSO (0.1%) or 5-aza-2′deoxycytidine (500 nM) for 96 hours.
Trichostatin A (50 ng/ml) was added for the last 24 hours of incubation. Subsequently IGFBP7 expression was analysed by quantitative PCR. Values
represent the mean ± SD of three independent experiments performed in triplicates. Asterisks indicate statistical significance compared with the
control (* P < 0.05, ** P < 0.01, *** P < 0.001). (B) Pyrosequencing was performed along 328 base pairs within the IGFBP7 promoter region containing 37
CpG sites (schematic representation). The graph on the left displays the percentage of methylation of each individual CpG site for all samples analysed.
The graph on the right represents the corresponding IGFBP7 expression values in the samples used for pyrosequencing. Cycles indicate the mean
percentage of DNA methylation along all 37 CpG sites in the promoter region analysed.
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dian OS: NA vs. 63.3 months, P < 0.001) (Figure 3). As
optimal cut-offs for IGFBP7 expression were different
between the cohorts (see methods section), we applied
the same fraction of patients defined as “high” IGFBP7
expressers in the HM-cohort (46/274, 18.6%) to the LR-cohort (131/701, 18.6%), confirming the association with
EFS and OS (Additional file 3: Figure S1).
High expression of IGFBP7 was likewise associated
with poor risk cytogenetics, most notably translocation
t(4;14)(P < 0.0001) and gain of 1q21 (P = 0.039). No sig-
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Figure 3 High IGFBP7 expression is predictive for poor outcome. IGFBP7 expression was analysed in CD138+ purified MM cells of newly
diagnosed, previously untreated myeloma patients of the Heidelberg-Montpellier group (HM; n = 247), as well as for validation purposes in the
independent Little-Rock (LR; n = 701) patient cohort as depicted in the Methods section. In both patient series, high IGFBP7 expression was
associated with worse event-free (A, C) and overall survival (B, D).
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The association between IGFBP7 expression levels and
t(4;14) was further validated by an in-silico analysis of
two additional publically available GEP-datasets [28,29].
In both, IGFBP7 expression was significantly higher in the
GEP-defined MMSEThigh expressing (typically t(4;14)
positive) patients compared to the other molecular sub-
groups (Additional file 5: Figure S3).
High IGFBP7 expression levels were also associated
with the GEP-based proliferation index (GPI) for the
HM (R = 0.21, P = 0.008) and LR group (R = 0.22, P =
0.037), which in turn is associated with adverse sur-
vival. IGFBP7 expression was not associated withtumour mass surrogates such as ISS stage or beta 2
microglobulin (B2M) levels.
IGFBP7 impacts on myeloma cell proliferation and viability
Exposure to recombinant human IGFBP7 (rhIGFBP7)
weakly but significantly reduced viable cell numbers in 6
of 7 HMCLs in a dose dependent manner (relative via-
bility compared to control: 0.68 ± 0.05 - 0.91 ± 0.02,
P < 0.05). In RPMI8226, treatment with rhIGFBP7 at
10 μg/ml similarly led to a minor reduction of viable cell
numbers by 7.8 ± 4.9% compared to control, although not
statistically significant (P = 0.05)(Figure 4A). In line with
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Figure 4 (See legend on next page.)
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Figure 4 IGFBP7 inhibits myeloma cell proliferation. MM cell lines (A) and primary MM cells (B) were treated with PBS/BSA 0.1% or recombinant
human IGFBP7 (rhIGFBP7) at the indicated concentrations for 96 hours. Primary cells were treated with IGFBP7 at 10 μg/ml. Viable cell numbers were
evaluated as outlined in the methods section. (C) Proliferation of MM cells was assessed by BrdU assay. HMCLs were treated for 72 hours with PBS/BSA
0.1% or rhIGFBP7 at the indicated concentrations. BrdU was added for the last 19 hours of incubation. Proliferation was assessed by measuring
absorbance at 450 nm. (D) Expression of p21 was analysed by quantitative PCR after 24 hour treatment with PBS/BSA 0.1% or rhIGFBP7 at
80 μg/ml. (E) Apoptosis of HMCLs was determined by Annexin V and 7-AAD staining after a 72 hour incubation period in the presence of
PBS/BSA 0.1% or rhIGFBP7 at the indicated concentrations. Graphs represent the mean (% positive cells on FACS) of three independent experiments
performed in duplicates. (F) KMS-12-BM and MM.1S were cultured in Syn-H serum free medium in the presence of rhIGFBP7, IGF-1 and/or insulin at
the indicated concentrations for 96 hours before viable cell numbers were determined. (A-D, F) Values represent the mean ± SD of three independent
experiments performed in triplicates and mean ± SD of triplicate experiments for primary MM cells. Asterisks indicate statistical significance compared
with the control (* P < 0.05, ** P < 0.01, *** P < 0.001).
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istical significance in 2 of 4 samples (Figure 4B). Analysis
of proliferation by BrdU assay mirrored the viability assess-
ment, showing weakly reduced proliferation of MM cells
exposed to IGFBP7 (BrdU positive cells relative to control:
0.92 ± 0.04 and 0.69 ± 0.16 with 20 μg/ml rhIGFBP7 in
OPM-2 and NCI-H929, respectively; P < 0.05) (Figure 4C).
Analysis of cell cycle inhibitory proteins after short-term
treatment with rhIGFBP7 showed a significant upregula-
tion of p21 in OPM-2 and MM.1S (relative induction
2.7 ± 0.68 and 1.9 ± 0.45 compared to control, respectively;
P < 0.05) (Figure 4D), while no significant changes were
observed in the expression levels of p16 and p27 (data not
shown). In contrast, no induction of apoptosis in MM
cells could be observed related to IGFBP7 exposure
(Figure 4E).
As IGFBP7 harbors binding sites for IGF-1 and insulin
we also examined whether IGFBP7 alters the stimulatory
activity of these growth factors. IGF-1 and insulin at
0.01-10 ng/ml potently stimulated the survival in 2 of 4
MM cell lines in Syn-H serum free medium (IGF-1
10 ng/ml: 2.1 ± 0.2 and 10.0 ± 2.7 fold viable cells com-
pared to control in KMS-12-BM and MM.1S, respect-
ively; insulin 10 ng/ml: 1.3 ± 0.02 and 8.6 ± 2.0), which
was not abrogated by combined treatment with 10 μg/ml
rhIGFBP7 (Figure 4F).
MM cells induce downregulation of IGFBP7 in BMSCs
We next characterized the expression of IGFBP7 in BM
stromal cells. IGFBP7 expression was 31 times higher in
BMSC TERT+ and 11 fold higher in primary (normal)
BMSCs compared to peripheral blood mononuclear
cells. In comparison with OMP-2, the highest expressing
MM cell line in our analysis, IGFBP7 expression was 37
fold higher in BMSC TERT+ cells and 13 fold higher in
primary BMSCs.
Co-cultures of BMSC TERT+ cells and HMCLs showed
a significant downregulation of IGFBP7 in BMSCs in the
presence of 4 of 5 HMCLs in a contact dependent manner
(relative expression compared to control: 0.06 - 0.50;
P < 0.05) (Figure 5A). Similar results were obtained using
primary MM cell samples (P < 0.001) (Figure 5B). Thus,MM cells have the capacity to significantly downregulate
the expression of IGFBP7 in BM stromal cells, which
highly express IGFBP7 in monoculture. When IGFBP7
expression levels in whole BM samples of myeloma
patients were compared with those of healthy donors,
significantly lower levels in the MM samples were like-
wise found (P = 0.012) (Figure 5C).
IGFBP7 promotes osteoblast development and might
protect from myeloma bone disease
As BMSCs have multilineage potential and can differen-
tiate into osteoblasts, we were interested in the role of
IGFBP7 in osteoblast development. IGFBP7 gene expres-
sion increased during the course of differentiation of pri-
mary (ND) BMSCs (Figure 6A) and treatment with
rhIGFBP7 further stimulated osteoblast formation, indi-
cated by a dose dependent increase in alkaline phosphat-
ase activity at day 7 (1.42 ± 0.29 fold increase compared to
control; P < 0.05) and 14 (1.81 ± 0.18 fold increase com-
pared to control, P < 0.001 ) of osteogenesis (Figure 6B).
Interestingly, we also observed a significant reduction in
Dickkopf-1 expression with rhIGFBP7 treatment during
osteogenesis (0.22 ± 0.06 fold decrease compared to con-
trol; P < 0.05) but no change in other OB marker genes
such as Runx2, Col1A and Dlx5 (data not shown).
As IGFBP7 was shown to bind activin A [17] we stud-
ied whether rhIGFBP7 treatment could overcome the in-
hibitory action of activin A on osteogenesis. As expected,
activin A demonstrated osteoblast inhibitory properties
reflected by a dose dependent decrease of alkaline phos-
phatase activity. Importantly, treatment with rhIGFBP7
was able to partially reverse this effect in primary and im-
mortalized BMSCs (Figure 6C-D). In our patient series we
observed significantly lower expression levels of IGFBP7
in MM cells of patients with advanced bone disease com-
pared to patients with no osteolytic lesions (Figure 6E).
Discussion
Various soluble factors have been identified in the sig-
naling crosstalk between myeloma and stromal cells in-
cluding IGF-1, IL6, DKK-1, RANKL and activin A
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Figure 5 Myeloma cells downregulate IGFBP7 in BMSCs. Co-culture of hBMSC TERT+ cells and MM cell lines (A) or primary MM cells (B) was
performed in the presence or absence of transwell inserts for 72 hours. Human BMSC TERT+ monocultures served as control. Direct contact cultures
were separated by MACS sorting previous to RNA isolation of the CD138-negative fraction. IGFBP7 mRNA levels were analysed by quantitative PCR and
compared to the control. Values represent the mean ± SD of three independent experiments performed in triplicates for MM cell lines and mean ± SD
of triplicate experiments for primary MM cells. (C) Downregulation of IGFBP7 in the myeloma microenvironment was confirmed by GEP analysis of
whole bone marrow (WBM) samples obtained from healthy donors (ND) and newly diagnosed myeloma patients (MM). Asterisks indicate statistical
significance compared with the control (* P < 0.05, ** P < 0.01, *** P < 0.001).
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binding sites for IGF-1, insulin [15], VEGFA [16] and
activin A [17] as a potential novel player in the patho-
genesis of MM, including myeloma bone disease. BMPs
are known to induce apoptosis in MM cells [12,13], so
upregulation of BMP antagonists might be envisaged to
be used as a protective mechanism by myeloma cells.
Median IGFBP7 expression levels, although IGFBP7
displayed a heterogenous expression profile, were found
to be downregulated in malignant plasma cells com-
pared to their normal counterparts, suggesting that
myeloma cells do not rely on the BMP antagonistic ac-
tivity of IGFBP7.We show that IGFBP7 downregulation in MM cells
can be explained by promoter methylation. Such a
downregulation of IGFBP7 by promoter methylation
was previously observed in solid tumours including
melanoma, prostate, lung and breast cancer as well as
T-ALL, suggesting a common mechanism in cancer
[19,21,30-32]. Plasma cells from MGUS patients already
display reduced IGFBP7 expression, indicating that de-
regulation of IGFBP7 might occur early in the course of
the disease.
IGFBP7 belongs to the family of insulin like growth
factor binding proteins (IGFBPs) consisting of six high-
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Figure 6 IGFBP7 promotes osteogenesis and is associated with myeloma bone disease. (A) Primary BMSCs were cultured in osteogenic
medium for 21 days. IGFBP7 expression was analysed during osteogenesis by quantitative PCR at the indicated time points. The graph represents the
relative expression compared to day 0 of osteogenesis. (B) Alkaline phosphatase activity in primary BMSCs was determined at days 7 and 14 of
differentiation in the presence or absence of rhIGFBP7 (1 or 10 μg/ml) and is displayed relative to the control (PBS/BSA 0.1%). For neutralization
experiments, alkaline phosphatase activity in primary human BMSCs (C) and BMSC TERT+ cells (D) was analysed at day 14 of osteogenesis in the
presence of activin A (50 or 100 ng/ml) and/or rhIGFBP7 (10 μg/ml). Results are displayed relative to the control (PBS/BSA 0.1%). (A-D) Values represent
the mean ± SD of three independent experiments performed in triplicates. (E) IGFBP7 expression was analysed with regard to the severity of myeloma
bone disease. Grey data points indicate an absent, black data points a present Affymetrix detection call. Asterisks indicate statistical significance
compared with the control (* P < 0.05, ** P < 0.01, *** P < 0.001).
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mechanisms [33]. Contrary to other family members, in
particular IGFBP3, IGFBP7 possesses low binding affin-
ity for IGFs [15,34]. Accordingly, unlike IGFBP3 [6],
IGFBP7 was not able to antagonize the growth stimula-
tory activity of IGF-1 and insulin on MM cell lines.
Previous studies indicated a role for IGFBP7 as
tumour suppressor in several solid malignancies includ-
ing melanoma, hepatocellular carcinoma, thyroid, breast,
bladder and colon cancer by either direct induction ofapoptosis and/or inhibition of tumour growth by deregu-
lation of p16, p21, p53 and ERK signaling [19,26,35-38].
However, results regarding the role of IGFBP7 in solid
tumours are inconsistent and recent studies provide a
more complex picture of IGFBP7 in different entities. In
glioblastoma, IGFBP7 was shown to stimulate tumour
cell proliferation and angiogenesis of brain endothelial
cells [39,40]. Similarly, elevated IGFBP7 expression was
detected in specific stages of colorectal cancer and si-
lencing of IGFBP7 reduced proliferation as well as colony
Bolomsky et al. Journal of Hematology & Oncology  (2015) 8:10 Page 10 of 14formation in colorectal cancer cell lines [41]. Expression of
IGFBP7 was also detected in cancer-associated fibroblasts,
endothelial cells, mesenchymal tumours and malignant epi-
thelial cells with a mesenchymal phenotype. In the latter,
loss of IGFBP7 significantly impaired the anchorage inde-
pendent growth of tumour cells. Furthermore, IGFBP7 ex-
pression in cancer stromal cells supported the growth of
colon cancer cells [41]. These findings establish a complex
variety of functions for IGFBP7 depending on the malig-
nancy investigated.
In haematological malignancies, IGFBP7 was found to
be associated with BAALC expression in T-ALL and to
correlate with poor survival [26]. Similarly, in B-cell ALL
IGFBP7 expression in BMSCs was found to be associated
with asparaginase resistance and decreased leukemia-free
survival [27]. In our study, high expression levels of
IGFBP7 predicted poor outcome in two large and inde-
pendent cohorts of MM patients. Whereas the mean
values and standard deviations (5.564 ± 3.213 vs. 3.155 ±
1.966) as well as the percentage of patients expressing
IGFBP7 as defined by the PANP algorithm (marginal and
present, 44.9 vs. 12.9%) significantly differed between the
HM- and LR-cohort, the prognostic impact of IGFBP7 ex-
pression was comparable between both cohorts. Observed
differences in frequency and height of expression are most
likely due to different amplification protocols used (double
vs. single amplification) [42-44].
IGFBP7 expression in MM cells was linked to prog-
nostically adverse chromosomal aberrations such as
translocation t(4;14) and amplification 1q21. The mul-
tiple myeloma SET domain (MMSET) protein, specific-
ally overexpressed in t(4;14) myeloma, is a histone
methyl transferase shown to modulate DNA methyla-
tion, thereby inducing the activation of specific target
genes [45]. Interestingly, IGFBP7 expression was found
to be regulated by MMSET in myeloma cells [45] which
is in line with our observation of higher IGFBP7 tran-
script levels in t(4;14) cases. The association between
MMSET expression and expression of IGFBP7 was con-
firmed by in-silico analysis of two open-source GEP
datasets. This suggests that IGFBP7 represents a novel
marker of high-risk myeloma, defined by an epigenetic
signature and regulated by MMSET.
The growth attenuating effects of IGFBP7 we observed
in vitro were rather small and evident only at high IGFBP7
concentrations [46]. Moreover, we show that, in clinical
myeloma samples, IGFBP7 expression is associated with
higher myeloma cell proliferation, in turn associated with
adverse prognosis. The phenotype of MMSET expressing
myeloma seems to overrule the weak inhibitory activity of
IGFBP7 on myeloma cell proliferation. Thus, rather than
being mechanistically involved in the poor outcome,
IGFBP7 might rather be seen as a marker associated with
a high-risk disease phenotype.We show upregulation of IGFBP7 in BMSCs while
undergoing osteogenic differentiation and treatment with
exogenous rhIGFBP7 further stimulating osteoblast activ-
ity. IGFBP7 treatment led to a significant downregulation
of DKK1, a major osteoblast inhibitory molecule in MM
[9]. Furthermore, we were able to show that IGFBP7 can
neutralize the inhibitory effects of activin A on osteoblast
development. Activin A mediated inhibition of osteogen-
esis leads to uncoupling of the delicate balance between
bone formation and degradation thus contributing to
myeloma related bone destruction [10,47]. Our results
suggest that the downregulation of IGFBP7 in the mye-
loma microenvironment enables activin A to release its
full destructive potential.
Possibly, the lack of IGFBP7 in the microenvironment
is aggravated by low or absent intrinsic expression of
IGFBP7 in myeloma cells. In contrast, in myeloma cases
with high IGFBP7 expression the downregulation of this
molecule in the microenvironment might be counterba-
lanced by production in myeloma cells, possibly explain-
ing the correlation of higher intrinsic IGFBP7 expression
and absence of advanced bone disease. In line with this,
prior studies reported osteolytic lesions to occur less
frequently in myeloma cases harboring a translocation
t(4;14) [48].
Conclusions
Taken together, our results suggest that IGFBP7 might
play a dual role in the pathophysiology of MM. Main-
tained expression of IGFBP7 in myeloma cells represents
a novel prognostic marker linked to prognostically ad-
verse chromosomal aberrations and a specific epigenetic
profile. In stromal cells in the vicinity of MM cells
IGFBP7 expression is suppressed, releasing the full po-
tential of osteoblast inhibitory molecules like activin A,
which then promote myeloma bone disease. In addition,
these findings might provide a mechanistic link for the




Patients presenting with previously untreated MM (n =
332) or monoclonal gammopathy of unknown signifi-
cance (MGUS; n = 22) at the University Hospitals of
Heidelberg and Montpellier (HM group) as well as 10
healthy normal donors have been included in the study
approved by the Heidelberg ethics committee (#229/
2003 and S-152/2010) after written informed consent
was obtained in accordance with the Declaration of
Helsinki. Patients were diagnosed, staged and response
to treatment assessed according to standard criteria.
Normal bone marrow plasma cells and myeloma cells
were purified as previously published [13,44]. Memory
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(PPCs; n = 10) were obtained as reported [49]. Aliquots
of unpurified whole bone marrow from myeloma pa-
tients (n = 154) and healthy donors were obtained after
NH4 lysis.
Bone disease was assessed by conventional X-ray and
whole body CT scan and graded as 0 (normal bone
structure), 1 (osteopenia/osteoporosis), 2 (1–3 osteo-
lyses) or 3 (major structural damage, >3 osteolyses) as
described previously [44].
The prognostic impact of IGFBP7 expression data was
validated on an independent cohort of 701 newly diag-
nosed, therapy-requiring patients treated within the total
therapy 2 or 3 protocol, respectively (LR group), for
whom gene expression data are publicly available (see
below) [50,51]. All patients in both cohorts, i.e. the HM-
and the LR-group, received high-dose chemotherapy
followed by autologous stem cell transplantation.
Cells and culture conditions
Human multiple myeloma cell lines (HMCLs) U266, KMS-
12-BM, OPM-2, NCI-H929, SK-MM-1 and RPMI8226 were
obtained from the German Collection of Microorganisms
and Cell Cultures (Braunschweig, Germany). MM.1S cells
were kindly provided by Dr Steven Rosen (Northwestern
University, Chicago, IL). All HMCLs were cultivated in
RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine and
100 U/ml penicillin/streptomycin (Gibco).
A human bone marrow mesenchymal stromal cell
line immortalized by enforced expression of telomerase
(hBMSC TERT+) was kindly provided by Dr Dario
Campana (St. Jude Children’s Research Hospital, Memphis,
TN) and cultured in RPMI-1640 medium supplemented
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin and 1 μM hydrocortisone (Sigma-Aldrich).
Primary human BMSCs (Lonza) were cultured in α-MEM
(Gibco) supplemented with 10% FBS, 2 mM L-Glutamine,
100 U/ml penicillin/streptomycin and 1 ng/ml FGF-2
(Peprotech).
For co-culture experiments, 0.25 × 106 TERT+ hBMSCs
were seeded in 6-well plates and cultured over night be-
fore 0.5 × 106 MM cells were added per well for 72 hours
in the presence or absence of transwell inserts (0.4 μm
pore size; BD). Direct contact cultures were MACS sorted
by CD138 selection previous to RNA isolation of the
CD138-negative population. Purity of the negative sort
was ≥ 90% by cytological assessment.
Cytotoxicity assay
Cell Counting Kit-8 (Sigma) was used to analyze the
impact of recombinant human IGFBP7 (rhIGFBP7;
Peprotech) on myeloma cell growth following the man-
ufacturer’s directions. In brief, 2 × 104 cells per wellwere seeded in flat-bottomed 96-well plates (Iwaki) in
the presence of rhIGFBP7 (0–10 μg/ml). Neutralization
experiments with recombinant human IGF-1 (10 or
100 ng/ml) (R&D Systems), insulin (10 or 100 ng/ml)
(Roche Diagnostics) and IGFBP7 (1 or 10 μg/ml) were
performed in serum free Syn-H medium (ABCell-Bio)
according to Sprynski et al. [6]
BrdU assay
Proliferation of myeloma cells was assessed by BrdU
assay (Calbiochem) following the manual. BrdU label
was added for the last 19 hours of the culture period.
Proliferation was determined by absorbance measure-
ment at 450 nm using a HTS 7000 Bio Assay Reader
(Perkin Elmer).
Flow cytometry
Intracellular staining of IGFBP7 was performed using the
BD Cytofix/Cytoperm™ Plus Kit (BD Biosciences) accord-
ing to the manual. After fixation and permeabilization,
cells were incubated with the primary goat-anti-human
IGFBP7 antibody (sc-6064; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) or the corresponding isotype con-
trol (sc-3887; Santa Cruz) for 30 min at 4°C. Thereafter
cells were washed and incubated for 30 min at 4°C with a
secondary PE-conjugated donkey-anti-goat antibody
(sc-3857; Santa Cruz). Analysis was performed on a
FACScan (BD Biosciences).
Induction of apoptosis was determined by FACS ana-
lysis of Annexin V/7-AAD stainings (BD Biosciences).
HMCLs were seeded at a concentration of 2.5 ×105/ml
and treated with either PBS/BSA 0.1% (control) or
rhIGFBP7 (10–20 μg/ml) for 72 hours. Cells were incu-
bated for 15 min with Annexin V and 7-AAD in the dark
before performing analysis.
Quantitative RT-PCR
Total RNA was isolated using RNeasy kit (Qiagen) and
cDNA synthesis was performed with M-MuLV reverse
transcriptase (New England Biolabs). IGFBP7, p16, p21,
p27, Runx2, Dlx-5, Col1A and DKK-1 expression levels
were analysed by quantitative PCR (qPCR) using TaqMan
Universal PCR Master Mix and pre-designed TaqMan
gene expression assays (Applied Biosystems). RPLPO
served as endogenous control. Reactions were carried out
in 25 μl volumes and run on the ABI Prism 7300 platform
(Applied Biosystems). All samples were run at least in
duplicates.
Methylation
For IGFBP7 induction experiments HMCLs were
seeded at 2 ×105/ml and cultivated in the presence of
0.1% DMSO (control) or 500 nM 5-aza-2′-deoxcytidine
(aza; Sigma) for 96 hours. Trichostatin A (TSA; Sigma)
Bolomsky et al. Journal of Hematology & Oncology  (2015) 8:10 Page 12 of 14was added at a concentration of 50 ng/ml for the last
24 hours of the culture period.
Analysis of the IGFBP7 promoter methylation status
was performed by varionostic GmbH (Ulm, Germany)
using pyrosequencing technology.
Osteogenic differentiation
For osteoblast development, BMSCs were seeded at a
density of 12500–25000 per cm2 and grown to 70-80%
confluence. Osteoblast differentiation was initiated by
changing the medium to α-MEM supplemented with
15% FBS, 2 mM L-Glutamine, 100 U/ml penicillin/
streptomycin, 10 nM dexamethasone (Sigma), 50 μg/ml
ascorbic acid (Sigma) and 10 mM β-glycerophosphate
(Sigma). Osteogenic medium was changed every 3–4
days. Recombinant human IGBFP7 (1 or 10 μg/ml) and/
or activin A (50 or 100 ng/ml) (Peprotech) were added
with every medium change. Cells treated with PBS/BSA
0.1% served as control.
Alkaline phosphatase activity assay
Alkaline phosphatase activity was determined at day 14
of differentiation using the AttoPhos® AP Fluorescent
Substrate System (Promega) following the manual.
Fluorescence was measured at 595 nm with excitation
at 430 nm. A standard curve was obtained by diluting
the supplied Calibrator solution (500 ng BBT/ml) in
AttoPhos buffer.
Gene expression profiling
Gene expression profiling was performed as previously
published [44] using U133 2.0 plus arrays according to
the manufacturer’s instructions (Affymetrix, Santa
Clara, CA, USA). Expression data are deposited in Array
Express under the accession numbers E-MTAB-317 as
well as E-TABM-1138 and Gene Expression Omnibus
GSE24080 (the latter two for the LR group). When differ-
ent probe sets were available for the same gene, we chose
the probe set yielding the maximal variance and the high-
est signal.
Interphase fluorescence in situ hybridization
Analyses were performed on CD138-purified plasma
cells as described [52] using probes for the detection of
numerical aberration of the chromosomal regions 1q21,
5p15/5q35, 9q34, 13q14.3, 15q22, 17p13, as well as the
IgH-translocations t(11;14)(q13;q32), and t(4;14)(p16.3;
q32) (Kreatech, Amsterdam, The Netherlands and
MetaSystems, Altlussheim, Germany).
Statistical analysis
Correlations (Spearman and Pearson) and survival ana-
lysis (Cox regression analysis) were performed using
SPSS statistics 17.0. For the analysis of in vitroexperiments, two-tailed unpaired t test was performed
using Prism 5 (GraphPad Software Inc., La Jolla, CA,
USA). P-values <0.05 were considered to be statistically
significant.
Gene expression analyses were performed on GC-RMA
preprocessed data sets. To assess presence (“expressed”)
or absence (“not expressed”) of gene expression, the
“Presence-Absence calls with Negative Probesets”
(PANP) algorithm was used [53]. For the analysis of the
prognostic value of IGFBP7, patients with high and low
IGFBP7 expression in the HM cohort were delineated
using maximally selected rank statistics as implemented
in the maxstat R package (http://cran.r-project.org/
web/packages/maxstat/index.html). The survival func-
tion was assessed by means of the Kaplan-Meier
method (rms package in R). The log rank test was used
to test for statistically significant survival curve differ-
ences. An effect was considered as statistically signifi-
cant if the P-value of its corresponding statistical test
was not higher than 5%. All computations were per-
formed using R 3.1.0 (http://www.r-project.org/) and
Bioconductor 2.14.
For validation of the impact of IGFBP7 expression on
survival, cel-files from 701 patients treated within the
total therapy 2 or 3 protocol (LR group), were prepro-
cessed as described above (GC-RMA), and the same
analysis strategy followed to obtain an optimal cut-off
(maxstat), i.e. the optimal cut-off was derived as the
mean of the cut-offs derived for EFS and OS. This separ-
ate analysis yielded two different cut-off values for the
HM- and LR-cohort. As the generation of two different
cut-offs for the HM and LR-group, i.e. delineating differ-
ent fractions of patients between in the different cohorts,
might give an over-optimistic validation, we likewise ap-
plied the fraction of patients defined as “high IGFBP7
expressing” from the HM-cohort (46/247, 18.6%) to the
LR-cohort (131/701, 18.6%).Additional files
Additional file 1: Table S1. BMP antagonist expression in CD138+
purified cells. Bold indicates differential expression in MM compared to
healthy donor bone marrow plasma cells (BMPCs).
Additional file 2: Table S2. BMP antagonist expression pattern in whole
bone marrow (WBM) samples. Bold indicates differential expression.
Additional file 3: Figure S1. EFS and OS in the LR cohort when the
same fraction of patients defined as “high” IGFBP7 expressers in the HM-
cohort (18.6%) was designated as high expressers in the LR-cohort. High
IGFBP7 expression was associated with adverse event-free (P<0.001) and
overall survival (P<0.002) by applying this criterion.
Additional file 4: Figure S2. IGFBP7 expression is associated with high
risk cytogenetics. Gene expression analysis of the HM-patient cohort
revealed that high IGFBP7 expression levels were associated with poor
risk cytogenetic markers including (A) translocation t(4;14) and (C) amplification
1q21. Moreover, a trend was found regarding the more frequent presence of
deletion 13q in patients with high IGFBP7 expression values (D). No association
Bolomsky et al. Journal of Hematology & Oncology  (2015) 8:10 Page 13 of 14was observed for (B) translocation t(11;14) and (E) deletion 17p. Grey data
points indicate an absent, black data points a present Affymetrix detection call.
Additional file 5: Figure S3. IGFBP7 expression is elevated in MMSET
defined molecular subgroups of myeloma. IGFBP7 expression was analysed
in two publically available GEP datasets published by (A) Zhan et al. [33] and
(B) Agnelli et al. [34]. Both datasets classified MM cases into distinct
molecular subgropus based on microarray experiments. (A) IGFBP7
expression was significantly elevated in the MMSET (MS) overexpressing
subgroup compared to five other GEP-defined subgroups. In addition,
IGFBP7 expression tended to be elevated in the MS subgroup compared to
the t(11;14) associated cyclin D1 (CD1) overexpressing samples. The other
subgoups were defined by a proliferation (PR), low bone involvement (LB),
hyperdiploid (HY), t(6;14) associated cyclin D (CD2) and MAF (MF)
expression based GEP profile. (B) Analysis of the dataset from Agnelli
et al. [34] confirmed overexpression of IGFBP7 in the MMSET defined
molecular subgroup of MM (TC4). The other subgroups were defined
by cyclin D overexpression (TC1), hyperdiploid status (TC2) and MAF
overexpression (TC5.) TC3 was defined by the lack of association with
any of the other subgroups. Asterisks indicate statistical significance
compared with the other molecular subgroups (* P < 0.05). Horizontal
lines represent median IGFBP7 expression with interquartile range.
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